Cemdisiran, Pozelimab
R3918-PNH-2050
Phase 3 small_molecule active
Quick answer
Cemdisiran, Pozelimab for Paroxysmal nocturnal hemoglobinuria (PNH) is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Paroxysmal nocturnal hemoglobinuria (PNH)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active